

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT  
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 30, 2013

**Ohr Pharmaceutical, Inc.**  
(Exact name of registrant as specified in its charter)

---

Delaware  
(State or other Jurisdiction  
of Incorporation)

333-88480  
(Commission File Number)

#90-0577933  
(IRS Employer  
Identification No.)

---

**489 5th Ave, 28th Floor, New York, NY**  
(Address of Principal Executive Offices)

**10017**  
(Zip Code)

---

Registrant's telephone number, including area code: (212)-682-8452

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

On April 30, 2013, the Board of Directors of Ohr Pharmaceutical Inc., (the "Company") elected a new Director, Thomas M. Riedhammer, Ph.D., whose term will end at the 2014 annual meeting of shareholders.

There are no arrangements or understandings between Dr. Riedhammer and any other person pursuant to which Dr. Riedhammer was selected as a Director.

Dr. Riedhammer was not appointed to any committee of the Board of Directors at the time of his election. However, the Company expects to appoint Dr. Riedhammer to the Audit Committee in the event the Company is listed on a Nasdaq market or a national exchange.

Since the beginning of the Company's last year, there have not been any transactions, or currently proposed transactions, or series of similar transactions, in which the Company was a party and in which Dr. Riedhammer had a direct or indirect material interest.

As an inducement to serve as a director, the Company granted to Dr. Riedhammer options to purchase 350,000 shares of Company Common Stock at \$1.58 per share, of which 87,500 are vested and an additional 87,500 options will vest on each of the first three anniversaries of grant, so long as he continues as director.

Dr. Riedhammer, 65, most recently served as Chairman of Sirion Therapeutics Inc, a position he held since 2007. Prior to that, Dr. Riedhammer served as Chief Operating Officer of Presby Corp., a medical device company engaged in the research and development of treatments for eye disorders. Prior to Presby Corp., Dr. Riedhammer served as President and Senior Vice President of Worldwide Pharmaceuticals at Bausch and Lomb from 1994 to 2000. He also held various other positions at Bausch and Lomb including: Senior Vice President, and Chief Technical Officer from 1998 to 2000, Senior Vice President and President for Worldwide Pharmaceutical, Surgical, and Hearing Care Products from 1994 to 1998, and Vice President from 1993 to 1994. He was a corporate Vice President of Paco Pharmaceuticals and President of Paco Research Corp from 1984 to 1991. Dr. Riedhammer began his career at Bausch & Lomb as a Research Chemist and was its Director, Lens Care Products R&D.

He has served as Chairman and Director of Prevent Blindness Florida, Director of Prevent Blindness America, Sjogren's Syndrome Foundation as secretary and Junior Achievement International. Dr. Riedhammer holds a B.A. in Chemistry and a Ph.D. in Electrochemistry from State University of New York at Buffalo.

### ITEM 8.01 OTHER ITEMS.

On May 2, 2013, the Company issued a press release announcing the appointment of Thomas M. Riedhammer to the Board of Directors.

A copy of the press release is being furnished as exhibit 99.1 to form 8K.

Exhibit No.	Description
99.1	<a href="#">Press Release Dated May 2, 2013</a>

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 2, 2013

OHR PHARMACEUTICAL, INC.

By: /s/ Dr. Irach Taraporewala  
Dr. Irach Taraporewala  
President and CEO

---

### **Ohr Pharmaceutical Appoints Thomas M. Riedhammer to Board of Directors**

NEW YORK, NY--(PR Newswire -05/2/13)- Ohr Pharmaceutical Inc. (OTCQB:OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced the appointment of Thomas M. Riedhammer, Ph.D., to its Board of Directors. Dr. Riedhammer has over 35 years of ophthalmic industry experience, working for large and small pharmaceutical companies engaged in drug development through commercialization.

“We are pleased to have brought on someone of Dr. Riedhammer’s caliber,” stated Dr. Irach Taraporewala, CEO of Ohr. “Tom’s proven expertise in building successful companies in the ophthalmic pharmaceutical industry will be an immeasurable asset to Ohr at this important juncture in the company’s growth.”

“I am excited to join the team at Ohr Pharmaceutical,” commented Dr. Riedhammer. “Squalamine eye drops are a unique and potentially transformative product for wet-AMD patients, a large patient population currently being treated with chronic intravitreal injections directly into the eye. I look forward to contributing to the future growth of Ohr and providing benefit for patients in need.”

Ira Greenstein, Chairman of the Board of Directors, added, “With our recent financing providing us with sufficient capital until 2015, anticipated enrollment milestones and a potential listing on Nasdaq on the horizon, it is a great time to welcome Dr. Riedhammer, with his wealth of experience in the development of ophthalmic companies, onto the team at Ohr.”

Dr. Riedhammer has over 35 years of ophthalmic industry expertise. Most recently, Dr. Riedhammer was Chairman of Sirion Therapeutics, where he was instrumental in raising over \$100 million dollars of private equity and the subsequent FDA approval and launch of two ophthalmic products in the U.S. Prior to Sirion, Dr. Riedhammer served as the Chief Operating Officer of Presby Corp., a medical device company engaged in the research and development of treatments for eye disorders, taking the company through clinical trials and a successful sale to CibaVision. Prior to Presby Corp, Dr. Riedhammer served as a senior corporate Vice President, member of the management executive committee, Chief Technical Officer and President of Global Pharmaceuticals for Bausch & Lomb, where he was involved with numerous acquisitions and licensing of ophthalmic products for the U.S. and European markets, and played an important role in the successful growth of Bausch and Lomb’s U.S. pharmaceutical business. Dr. Riedhammer began his career at Bausch & Lomb as a research chemist where he was awarded 12 U.S. patents and was responsible for the development of the Renu and Sensitive Eyes product lines. He holds a B.A. in Chemistry and a Ph.D. in Electrochemistry from State University of New York at Buffalo.

#### About Ohr Pharmaceutical Inc.

Ohr Pharmaceutical Inc. (OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the company can be found at [www.ohrpharmaceutical.com](http://www.ohrpharmaceutical.com).

---

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing, and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact:

Ohr Pharmaceutical Inc.

Investor Relations:

Tel: (877) 215-4813

Email: [ir@ohrpharmaceutical.com](mailto:ir@ohrpharmaceutical.com)

---